Milestone Pharmaceuticals Retained Earnings (Accumulated Deficit) 2018-2024 | MIST

Milestone Pharmaceuticals retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Milestone Pharmaceuticals Retained Earnings (Accumulated Deficit) 2018-2024 | MIST

Milestone Pharmaceuticals retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.3B
Vertex Pharmaceuticals (VRTX)$122B
Bristol Myers Squibb (BMY)$112.5B
Gilead Sciences (GILD)$111.9B
Regeneron Pharmaceuticals (REGN)$91.4B
CSL (CSLLY)$90.8B
GSK (GSK)$76.6B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$34.8B
BioNTech SE (BNTX)$25.9B
Biogen (BIIB)$25.3B
Illumina (ILMN)$24.5B
Moderna (MRNA)$20.6B
BeiGene (BGNE)$20.2B
Genmab (GMAB)$15.1B
Incyte (INCY)$14.6B
Exact Sciences (EXAS)$13.1B
BioMarin Pharmaceutical (BMRN)$12.6B
Insmed (INSM)$12.2B
Bio-Techne Corp (TECH)$12B
Vaxcyte (PCVX)$11.9B
Sarepta Therapeutics (SRPT)$11.7B
QIAGEN (QGEN)$10B
Exelixis (EXEL)$9.8B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Roivant Sciences (ROIV)$8.5B
Legend Biotech (LEGN)$8B
Repligen (RGEN)$7.8B